Abstract
In developed countries, cardiovascular disease is one of the leading causes of death. Statins are abundantly prescribed to reduce the risk of coronary artery disease by lowering cholesterol. Genetic factors are thought to be partly responsible for the interindividual variation in the response to statins. This article reviews the most important studies conducted on pharmacogenetics of statins. Currently, there is no evidence to advocate pharmacogenetic testing before initiating therapy.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Anticholesteremic Agents / pharmacology
-
Anticholesteremic Agents / therapeutic use
-
Cardiovascular Diseases / etiology
-
Cardiovascular Diseases / genetics
-
Cardiovascular Diseases / prevention & control*
-
Coronary Artery Disease / etiology
-
Coronary Artery Disease / genetics
-
Coronary Artery Disease / prevention & control
-
Genetic Variation
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
-
Hypercholesterolemia / drug therapy*
-
Hypercholesterolemia / genetics
-
Pharmacogenetics / methods
-
Risk Factors
Substances
-
Anticholesteremic Agents
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors